Summary

Report Scope
This study offers a global view of the antibody drugs that have become key components of the pharmaceutical and biopharmaceutical markets. It analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when attached to cytotoxic agents such as antibody drug conjugates (ADCs).
BCC Research analyzed and made projections of each market and its applications, along with an analysis of the regulatory environment, new products and technological advances. Also included in the report are profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., and Merck KGaA.
Monoclonal antibodies are finding growing use in the treatment of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review of their applications in various disease sectors. The overall market for antibody drug products includes four primary areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.
This report excludes polyclonal antibodies, screening kits and diagnostic uses of mAbs. It also excludes the research applications of mAbs and therapeutic antibodies for veterinary use. The report excludes antibody products for COVID-19 and vaccine-based products.
The market is segmented by geographical region: North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further broken down by country as follows: North America—the U.S., Canada and Mexico; Europe—Germany, the U.K., France, Italy, Spain, and the Rest of Europe; Asia-Pacific—China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years, 2023 as the base year, and forecasts through 2029.
Report Includes
- 76 data tables and 55 additional tables
- An updated review of the global market for antibody drugs
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the overall market for antibody drugs, and corresponding market share analysis by type, manufacturing process, application, and region
- Description of antibody functions and how they compare with antigens, and a discussion of monoclonal antibodies (mAbs), including their history, advantages and disadvantages, types, manufacturing technologies and applications
- Coverage of new approvals, recalls, safety alerts and clinical trials of mAbs, as well as technical issues related to human anti-mouse antibody (HAMA), and factors affecting mAB drugs
- An assessment of the major technologies for the formulation of antibody drugs and their relation to biotechnology, immunology, pharmaceuticals, and biodefense companies
- Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., AbbVie Inc., Merck KGaA, and Amgen Inc.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Insights
Chapter 2 Market Overview
Antibodies and Antigens
Antibody Functions
Monoclonal Antibodies
History of Monoclonal Antibodies
Monoclonal Antibodies: Advantages and Disadvantages
Types of Monoclonal Antibodies
Manufacturing Technologies of Monoclonal Antibodies
Applications of Monoclonal Antibodies
Chapter 3 Market Dynamics
Drivers
Increasing Incidence of Cancer and Autoimmune Diseases
New Product Launches
Restraints
High Prices and Pricing Pressure
Side Effects and Limitations of mAbs
Opportunities
Licensing and Collaboration Agreements
Manufacturing Advances and Improving Product Yields
Chapter 4 Regulatory Aspects
Regulatory Scenario
Price Controls
New Approvals of Monoclonal Antibodies
Chapter 5 Emerging Technologies and Developments
Overview
Emerging Technologies
Bispecific Antibodies and Multi-Specific Antibodies
Antibody-Drug Conjugates
Antibody Fusion Proteins
AI and ML in Antibody Drug Engineering
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Market for Antibody Drugs, by Antibody Type
Human Monoclonal Antibodies
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
Global Market for Antibody Drugs, by Manufacturing Process
Mammalian Cell Culture
Microbial Cell Fermentation
Global Market for Antibody Drugs, by Application
Market by Application
Autoimmune Diseases
Solid Tumors
Lymphoma, Leukemia and Multiple Myeloma
Others
Geographic Breakdown
Global Market for Antibody Drugs, by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 7 Competitive Intelligence
Competitive Landscape
Market Share for Human Monoclonal Antibodies
Market Share for Humanized Monoclonal Antibodies
Market Share for Chimeric Monoclonal Antibodies
Chapter 8 New Developments and Clinical Trial Activities
New Developments and M&A Analysis
Clinical Trial Activities
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials
Chapter 9 Sustainability: An ESG Perspective in the Antibody Drugs Market
Sustainability in the Antibody Drugs Market
Understanding the ESG Data
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC
Chapter 10 Appendix
Methodology
Sources
Acronyms
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK KGAA
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI